WallStreetZenWallStreetZen

NASDAQ: BMEA
Biomea Fusion Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for BMEA

Based on 7 analysts offering 12 month price targets for Biomea Fusion Inc

Min Forecast
$3.00+48.51%
Avg Forecast
$9.43+366.78%
Max Forecast
$18.00+791.09%

Should I buy or sell BMEA stock?

Based on 7 analysts offering ratings for Biomea Fusion Inc.

Strong Buy
Strong Buy
4 analysts 57.14%
Buy
2 analysts 28.57%
Hold
1 analysts 14.29%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%
Although BMEA's forecast from analysts indicates a "Strong Buy", our proven Zen Rating quant model rates BMEA as a "Sell". Stocks with a Zen Rating of Sell have had an average return of -4.50% per year. Learn More

Be the first to know when Wall Street analysts revise their BMEA stock forecasts and price targets.

BMEA stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2025-08-28
lockedlocked$00.00+00.00%2025-08-11
lockedlocked$00.00+00.00%2025-08-06
lockedlocked$00.00+00.00%2025-08-06
lockedlocked$00.00+00.00%2025-06-03
HC Wainwright & Co.
Bottom 1%
1
BuyMaintains$18.00+791.09%2025-05-06
Barclays
Bottom 4%
4
HoldMaintains$3.00+48.51%2025-04-02

1 of 1

Forecast return on equity

Is BMEA forecast to generate an efficient return?

Company
-363.41%
Industry
130.77%
Market
-49.74%
BMEA's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is BMEA forecast to generate an efficient return on assets?

Company
-136.65%
Industry
47.39%
BMEA is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

BMEA earnings per share forecast

What is BMEA's earnings per share in the next 3 years based on estimates from 4 analysts?

Avg 1 year Forecast
-$1.64
Avg 2 year Forecast
-$1.50
Avg 3 year Forecast
-$1.11

BMEA revenue forecast

What is BMEA's revenue in the next 3 years based on estimates from 1 analyst?

Avg 1 year Forecast
$15.0M
Avg 2 year Forecast
$15.0M
Avg 3 year Forecast
$5.6M

BMEA vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
BMEA$2.02$9.43+366.78%Strong Buy
SKYE$3.86$13.00+236.79%Buy
INO$2.28$6.50+185.09%Buy
ANIX$3.60$9.00+150.00%Strong Buy
TARA$3.07$18.67+508.05%Strong Buy
View Top Biotech Stocks

Biomea Fusion Stock Forecast FAQ

Is Biomea Fusion Stock a good buy in 2025, according to Wall Street analysts?

The consensus among 7 Wall Street analysts covering (NASDAQ: BMEA) stock is to Strong Buy BMEA stock.

Out of 7 analysts, 4 (57.14%) are recommending BMEA as a Strong Buy, 2 (28.57%) are recommending BMEA as a Buy, 1 (14.29%) are recommending BMEA as a Hold, 0 (0%) are recommending BMEA as a Sell, and 0 (0%) are recommending BMEA as a Strong Sell.

If you're new to stock investing, here's how to buy Biomea Fusion stock.

What is BMEA's earnings growth forecast for 2025-2027?

(NASDAQ: BMEA) Biomea Fusion's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 5.14%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 15.23%.

Biomea Fusion's earnings in 2025 is -$112,091,000.On average, 4 Wall Street analysts forecast BMEA's earnings for 2025 to be -$97,742,741, with the lowest BMEA earnings forecast at -$118,421,951, and the highest BMEA earnings forecast at -$80,336,499. On average, 4 Wall Street analysts forecast BMEA's earnings for 2026 to be -$89,114,006, with the lowest BMEA earnings forecast at -$144,010,614, and the highest BMEA earnings forecast at -$59,508,518.

In 2027, BMEA is forecast to generate -$65,756,912 in earnings, with the lowest earnings forecast at -$94,023,458 and the highest earnings forecast at -$37,490,366.

What is BMEA's revenue growth forecast for 2025-2027?

(NASDAQ: BMEA) Biomea Fusion's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 85.29%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.87%.

Biomea Fusion's revenue in 2025 is $0.On average, 1 Wall Street analysts forecast BMEA's revenue for 2025 to be $892,627,770, with the lowest BMEA revenue forecast at $892,627,770, and the highest BMEA revenue forecast at $892,627,770. On average, 1 Wall Street analysts forecast BMEA's revenue for 2026 to be $892,627,770, with the lowest BMEA revenue forecast at $892,627,770, and the highest BMEA revenue forecast at $892,627,770.

In 2027, BMEA is forecast to generate $332,712,124 in revenue, with the lowest revenue forecast at $332,712,124 and the highest revenue forecast at $332,712,124.

What is BMEA's forecast return on assets (ROA) for 2025-2028?

(NASDAQ: BMEA) forecast ROA is -136.65%, which is lower than the forecast US Biotechnology industry average of 47.39%.

What is BMEA's Price Target?

According to 7 Wall Street analysts that have issued a 1 year BMEA price target, the average BMEA price target is $9.43, with the highest BMEA stock price forecast at $18.00 and the lowest BMEA stock price forecast at $3.00.

On average, Wall Street analysts predict that Biomea Fusion's share price could reach $9.43 by Aug 28, 2026. The average Biomea Fusion stock price prediction forecasts a potential upside of 366.78% from the current BMEA share price of $2.02.

What is BMEA's Earnings Per Share (EPS) forecast for 2025-2027?

(NASDAQ: BMEA) Biomea Fusion's current Earnings Per Share (EPS) is -$3.02. On average, analysts forecast that BMEA's EPS will be -$1.64 for 2025, with the lowest EPS forecast at -$1.99, and the highest EPS forecast at -$1.35. On average, analysts forecast that BMEA's EPS will be -$1.50 for 2026, with the lowest EPS forecast at -$2.42, and the highest EPS forecast at -$1.00. In 2027, BMEA's EPS is forecast to hit -$1.11 (min: -$1.58, max: -$0.63).

What is BMEA's forecast return on equity (ROE) for 2025-2028?

(NASDAQ: BMEA) forecast ROE is -363.41%, which is considered weak.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.